A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

(2014) Claire Fabre et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors

(2014) Rudolf Weide et al.   SpringerPlus

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

(2013) Dorien J. A. Lobbezoo et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

(2013) Monica M. Mita et al.   Clinical Breast Cancer

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

Targeting low molecular weight cyclin E (LMW-E) in breast cancer

(2011) Angela Nanos-Webb et al.   BREAST CANCER RESEARCH AND TREATMENT

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

(2010) Kamil Paruch et al.   ACS Medicinal Chemistry Letters

Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism

(2008) Gustavo Ortiz-Ferrón et al.   CELL RESEARCH